Total for the last 12 months
number of access : ?
number of downloads : ?
ID 109620
Title Transcription
イマチニブ ガ チョコウ シ チョウキ カンゼン カンカイ CR オ イジ シテ イル ショウチョウ GIST フクマク ハシュ サイハツ ノ 1レイ
Title Alternative
A case of recurrent gastrointestinal stromal tumor with peritoneal dissemination in which long-term complete remission was achieved with imatinib mesylate therapy
Author
Masamune, Katsuhiro Department of Surgery, Anan Kyoei Hospital
Toyota, Tsuyoshi Department of Surgery, Anan Kyoei Hospital
Takamura, Kazuhito Department of Surgery, Anan Kyoei Hospital
Kita, Yoshitaka Department of Surgery, Anan Kyoei Hospital
Sannomiya, Kenji Department of Surgery, Anan Kyoei Hospital
Keywords
gastrointestinal stromal tumor (GIST)
small intestine
peritoneal dissemination
complete remission
imatinib mesylate
Content Type
Journal Article
Description
We report the case of a patient with recurrent gastrointestinal stromal tumor (GIST) complicated with peritoneal dissemination who achieved long-term complete remission (CR) with imatinib mesylate therapy. A 64-year-old man was admitted to our hospital because of severe abdominal pain. Abdominal computed tomography (CT) showed free air and an intra-abdominal abscess. Perforation of the small intestine was diagnosed, and an emergency operation was performed. Two adjacent tumors (each,6cm in size), one of which was ruptured, were found by laparotomy in the jejunum and as a peritoneal dissemination. Jejunojejunostomy with the two adjacent tumors was performed and as much of the disseminated tumors as possible were resected. Histopathological analysis indicated a high-risk GIST of the small intestine.
Abdominal CT at 1.5 years after the initial operation showed multiple recurrent tumors due to peritoneal dissemination. The patient subsequently received imatinib mesylate therapy at 400mg/day, and 5 months later, abdominal CT showed no evidence of tumor recurrence. DNA analysis of the tumor revealed an exon 11 mutation in the c-kit gene. The patient continues to receive imatinib mesylate therapy (400mg/day), and CR of the recurrent tumors has been maintained for 8 years and 7 months.
Journal Title
四国医学雑誌
ISSN
00373699
NCID
AN00102041
Publisher
徳島医学会
Volume
69
Issue
1-2
Start Page
89
End Page
94
Sort Key
89
Published Date
2013-04-25
FullText File
language
jpn
TextVersion
Publisher